Eli Lilly and Company (NYSE:LLY – Get Free Report) announced its quarterly earnings data on Thursday. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.68 by $1.80, FiscalAI reports. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter last year, the business posted $7.02 EPS. The business’s quarterly revenue was up 38.6% compared to the same quarter last year.
Here are the key takeaways from Eli Lilly and Company’s conference call:
- Q3 revenue rose 39% to approximately $24 billion, driven by Mounjaro, Zepbound, and broad strength across oncology, immunology, and neuroscience. Lilly raised its 2026 guidance to $91–$92 billion in revenue and $35–$36 in non-GAAP EPS.
- The incretin franchise continued to accelerate, with Mounjaro and Zepbound generating more than $16 billion in combined quarterly revenue. The Medicare GLP-1 Bridge Program has served more than 500,000 prescriptions, with seven in 10 new bridge patients choosing a Lilly obesity medicine.
- Lilly reported encouraging pipeline and regulatory progress, including strong retatrutide results versus semaglutide, positive data for the eloralintide/tirzepatide combination, and U.S. approvals for weekly basal insulin Onswik, expanded pirtobrutinib use, and new tirzepatide and imlunestrant indications.
- Pricing remains a significant headwind, with U.S. realized price declining 10% excluding a favorable rebate adjustment, while expanded Medicare and Medicaid access and self-pay growth are expected to pressure net price per prescription in 2027. Management also cautioned that roughly $2 billion of 2026 one-time benefits will not recur next year.
- Lilly is investing heavily for long-term growth, breaking ground on $11.5 billion of new U.S. manufacturing capacity and adding pipeline assets through the AtaiBeckley and Merida acquisitions, while maintaining a broad set of late-stage programs across oncology, neuroscience, and immunology.
Eli Lilly and Company Stock Up 6.6%
Eli Lilly and Company stock traded up $84.70 during trading hours on Thursday, hitting $1,373.00. The company had a trading volume of 3,220,795 shares, compared to its average volume of 2,927,350. The firm has a market capitalization of $1.29 trillion, a P/E ratio of 45.95, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The firm’s fifty day moving average is $1,192.52 and its 200-day moving average is $1,089.35. Eli Lilly and Company has a fifty-two week low of $812.25 and a fifty-two week high of $1,408.38.
Eli Lilly and Company Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.
Key Stories Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Strong earnings and revenue beat: Third-quarter revenue rose 39% year over year to $24.4 billion, above the roughly $22.6 billion analyst estimate. Adjusted EPS was $7.48, well ahead of the $5.68 consensus and up from $7.02 a year earlier. Reuters earnings and outlook article
- Positive Sentiment: Higher full-year outlook: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion, lifting the midpoint by $5.5 billion. The increase signals that demand for its metabolic-care portfolio is exceeding prior expectations. Lilly third-quarter results and guidance
- Positive Sentiment: Mounjaro and Zepbound remain major growth engines: Mounjaro sales jumped 65% to $10.7 billion, while Zepbound revenue increased 49% to $5.35 billion. The results reinforced investor confidence in Lilly’s leadership of the diabetes and obesity-drug market. New York Post weight-loss drug demand article
- Positive Sentiment: Pipeline momentum improved: Phase 3 data showed experimental drug retatrutide produced greater A1C reduction and more than twice the weight loss of Ozempic 2 mg in adults with type 2 diabetes. The data strengthen Lilly’s competitive position against Novo Nordisk and support longer-term growth expectations. Lilly retatrutide trial results
- Neutral Sentiment: Investors should watch earnings quality: Quarterly revenue benefited from approximately $900 million in Jardiance milestones and rebate-related adjustments. Lilly also recorded substantial acquired in-process research and development charges, while reports noted a trimmed profit view tied to deal-related costs.
- Negative Sentiment: Insider selling is a secondary risk signal: Four Lilly executives sold shares during the past six months, with no reported open-market purchases. These transactions have not outweighed the earnings-driven optimism but may draw attention given the stock’s elevated valuation.
Insiders Place Their Bets
In other news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last three months. Insiders own 0.14% of the company’s stock.
Wall Street Analyst Weigh In
LLY has been the topic of a number of recent analyst reports. Sanford C. Bernstein reiterated an “outperform” rating and set a $1,450.00 price target on shares of Eli Lilly and Company in a research note on Monday. Guggenheim boosted their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research note on Friday, September 18th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 15th. Finally, Wall Street Zen downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Saturday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,320.25.
Read Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.
The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
